Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today.
Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow.
#TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs
Company Details
- Employees
- 3
- Address
- Yalelaan 62, Life Sciences Incubator Rm 2.05 Utrecht Science Park,netherlands
- Industry
- Biotechnology
- Website
- https://www.laigobio.com
- HQ
- Utrecht
Laigo Bio Questions
Laigo Bio's website is https://www.laigobio.com
Laigo Bio's LinkedIn profile is https://nl.linkedin.com/company/laigobio
Laigo Bio has
3 employees.
View email and phone details for 3
employees at Laigo Bio.
Laigo Bio's industry is
Biotechnology
Laigo Bio's top competitors are
Inverna Therapeutics,
Elkedonia,
Cyclomics,
Targed Biopharmaceuticals,
Cleara Biotech B.v.,
Crucible Therapeutics,
Glycostem Therapeutics,
Phlox Therapeutics,
Allergios,
Argobio Studio.
Laigo Bio's categories are Biotechnology
